Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma : a multicenter retrospective study
We conducted a multicenter study on anti-programmed cell death-1 monoclonal antibodies (anti-PD-1 mAbs) before/after allogeneic hematopoietic cell transplantation (allo-HCT) for Hodgkin lymphoma. Anti-PD-1 mAbs were administered to 25 patients before allo-HCT and to 20 after allo-HCT. In pre-allo-HCT setting, the median interval from the last administration to allo-HCT was 59 days. After allo-HCT, 12 patients developed non-infectious febrile syndrome requiring high-dose corticosteroid. The cumulative incidences of grade II-IV acute graft-versus-host disease (aGvHD) were 47.1%. Eight patients who had GvHD prophylaxis with post-transplant cyclophosphamide (PTCy) had less frequent aGvHD (grade II-IV, 14.6% versus 58.8%; P = 0.086). The 1 year overall survival (OS), relapse/progression, and non-relapse mortality rates were 81.3%, 27.9%, and 8.4%. In post-allo-HCT setting, the median interval from allo-HCT to the first administration was 589 days. The overall and complete response rates were 75% and 40%. At 100 days after anti-PD-1 therapy, the cumulative incidences of grade II-IV aGvHD, moderate-to-severe chronic GvHD, and grade 3-4 immune-related toxicity were 15.0%, 30.0%, and 30.0%. While the 1 year relapse/progression rate was 47.4%, the 1 year OS probability was 89.7%. In conclusion, immune-related complications were frequent despite modifications of GvHD prophylaxis or anti-PD-1 mAb dosing. In anti-PD-1-mAb-pretreated patients, PTCy-based GvHD prophylaxis may be effective.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
---|---|
Enthalten in: |
International journal of hematology - 112(2020), 5 vom: 03. Nov., Seite 674-689 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ito, Ayumu [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 24.11.2020 Date Revised 23.01.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s12185-020-02960-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM313235104 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM313235104 | ||
003 | DE-627 | ||
005 | 20231225150137.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12185-020-02960-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1044.xml |
035 | |a (DE-627)NLM313235104 | ||
035 | |a (NLM)32748216 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ito, Ayumu |e verfasserin |4 aut | |
245 | 1 | 0 | |a Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma |b a multicenter retrospective study |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.11.2020 | ||
500 | |a Date Revised 23.01.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a We conducted a multicenter study on anti-programmed cell death-1 monoclonal antibodies (anti-PD-1 mAbs) before/after allogeneic hematopoietic cell transplantation (allo-HCT) for Hodgkin lymphoma. Anti-PD-1 mAbs were administered to 25 patients before allo-HCT and to 20 after allo-HCT. In pre-allo-HCT setting, the median interval from the last administration to allo-HCT was 59 days. After allo-HCT, 12 patients developed non-infectious febrile syndrome requiring high-dose corticosteroid. The cumulative incidences of grade II-IV acute graft-versus-host disease (aGvHD) were 47.1%. Eight patients who had GvHD prophylaxis with post-transplant cyclophosphamide (PTCy) had less frequent aGvHD (grade II-IV, 14.6% versus 58.8%; P = 0.086). The 1 year overall survival (OS), relapse/progression, and non-relapse mortality rates were 81.3%, 27.9%, and 8.4%. In post-allo-HCT setting, the median interval from allo-HCT to the first administration was 589 days. The overall and complete response rates were 75% and 40%. At 100 days after anti-PD-1 therapy, the cumulative incidences of grade II-IV aGvHD, moderate-to-severe chronic GvHD, and grade 3-4 immune-related toxicity were 15.0%, 30.0%, and 30.0%. While the 1 year relapse/progression rate was 47.4%, the 1 year OS probability was 89.7%. In conclusion, immune-related complications were frequent despite modifications of GvHD prophylaxis or anti-PD-1 mAb dosing. In anti-PD-1-mAb-pretreated patients, PTCy-based GvHD prophylaxis may be effective | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Allogeneic hematopoietic cell transplantation | |
650 | 4 | |a Anti-PD-1 monoclonal antibody | |
650 | 4 | |a Hodgkin lymphoma | |
650 | 4 | |a Immune checkpoint inhibitor | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a PDCD1 protein, human |2 NLM | |
650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
650 | 7 | |a Cyclophosphamide |2 NLM | |
650 | 7 | |a 8N3DW7272P |2 NLM | |
700 | 1 | |a Kim, Sung-Won |e verfasserin |4 aut | |
700 | 1 | |a Matsuoka, Ken-Ichi |e verfasserin |4 aut | |
700 | 1 | |a Kawakita, Toshiro |e verfasserin |4 aut | |
700 | 1 | |a Tanaka, Takashi |e verfasserin |4 aut | |
700 | 1 | |a Inamoto, Yoshihiro |e verfasserin |4 aut | |
700 | 1 | |a Toubai, Tomomi |e verfasserin |4 aut | |
700 | 1 | |a Fujiwara, Shin-Ichiro |e verfasserin |4 aut | |
700 | 1 | |a Fukaya, Masafumi |e verfasserin |4 aut | |
700 | 1 | |a Kondo, Tadakazu |e verfasserin |4 aut | |
700 | 1 | |a Sugita, Junichi |e verfasserin |4 aut | |
700 | 1 | |a Nara, Miho |e verfasserin |4 aut | |
700 | 1 | |a Katsuoka, Yuna |e verfasserin |4 aut | |
700 | 1 | |a Imai, Yosuke |e verfasserin |4 aut | |
700 | 1 | |a Nakazawa, Hideyuki |e verfasserin |4 aut | |
700 | 1 | |a Kawashima, Ichiro |e verfasserin |4 aut | |
700 | 1 | |a Sakai, Rika |e verfasserin |4 aut | |
700 | 1 | |a Ishii, Arata |e verfasserin |4 aut | |
700 | 1 | |a Onizuka, Makoto |e verfasserin |4 aut | |
700 | 1 | |a Takemura, Tomonari |e verfasserin |4 aut | |
700 | 1 | |a Terakura, Seitaro |e verfasserin |4 aut | |
700 | 1 | |a Iida, Hiroatsu |e verfasserin |4 aut | |
700 | 1 | |a Nakamae, Mika |e verfasserin |4 aut | |
700 | 1 | |a Higuchi, Kohei |e verfasserin |4 aut | |
700 | 1 | |a Tamura, Shinobu |e verfasserin |4 aut | |
700 | 1 | |a Yoshioka, Satoshi |e verfasserin |4 aut | |
700 | 1 | |a Togitani, Kazuto |e verfasserin |4 aut | |
700 | 1 | |a Kawano, Noriaki |e verfasserin |4 aut | |
700 | 1 | |a Suzuki, Ritsuro |e verfasserin |4 aut | |
700 | 1 | |a Suzumiya, Junji |e verfasserin |4 aut | |
700 | 1 | |a Izutsu, Koji |e verfasserin |4 aut | |
700 | 1 | |a Teshima, Takanori |e verfasserin |4 aut | |
700 | 1 | |a Fukuda, Takahiro |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of hematology |d 1997 |g 112(2020), 5 vom: 03. Nov., Seite 674-689 |w (DE-627)NLM012627607 |x 1865-3774 |7 nnns |
773 | 1 | 8 | |g volume:112 |g year:2020 |g number:5 |g day:03 |g month:11 |g pages:674-689 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12185-020-02960-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 112 |j 2020 |e 5 |b 03 |c 11 |h 674-689 |